Jenna Voutsinas

3.7k total citations
78 papers, 1.6k citations indexed

About

Jenna Voutsinas is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Jenna Voutsinas has authored 78 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 23 papers in Pathology and Forensic Medicine and 11 papers in Genetics. Recurrent topics in Jenna Voutsinas's work include CAR-T cell therapy research (36 papers), Lymphoma Diagnosis and Treatment (23 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Jenna Voutsinas is often cited by papers focused on CAR-T cell therapy research (36 papers), Lymphoma Diagnosis and Treatment (23 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Jenna Voutsinas collaborates with scholars based in United States, South Africa and Canada. Jenna Voutsinas's co-authors include Qian Wu, David G. Maloney, Cameron J. Turtle, Alexandre V. Hirayama, Merav Bar, Stanley R. Riddell, Ana Cordeiro, Evandro D. Bezerra, Mohamed L. Sorror and Jordan Gauthier and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Jenna Voutsinas

65 papers receiving 1.6k citations

Peers

Countries citing papers authored by Jenna Voutsinas

Since Specialization

Citations

This map shows the geographic impact of Jenna Voutsinas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jenna Voutsinas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jenna Voutsinas more than expected).

Fields of papers citing papers by Jenna Voutsinas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jenna Voutsinas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jenna Voutsinas. The network helps show where Jenna Voutsinas may publish in the future.

Co-authorship network of co-authors of Jenna Voutsinas

This figure shows the co-authorship network connecting the top 25 collaborators of Jenna Voutsinas. A scholar is included among the top collaborators of Jenna Voutsinas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jenna Voutsinas. Jenna Voutsinas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Novel R Shiny Tool TVCurveTM for Survival Analysis with Time-Varying Covariate in Oncology Clinical Studies: Overcoming Biases and Enhancing Collaboration 2025 ·Transplantation and Cellular Therapy ·Yimei Li, Yang Qiao, (unknown), Jordan Gauthier, Qiang Zhang, Jenna Voutsinas, Wendy M. Leisenring, Ted Gooley, Corinne Summers, Alexandre V. Hirayama, Cameron J. Turtle, Rebecca Gardner, Jarcy Zee, Qian Wu	0
2	Impact of immunophenotype on clinical disease characteristics and outcomes in T‐cell prolymphocytic leukaemia 2025 ·British Journal of Haematology ·Christina Poh, Xueyan Chen, Jenna Voutsinas, Kikkeri N. Naresh, (unknown), Mazyar Shadman, Ryan C. Lynch, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, (unknown), Edus H. Warren, Stephen D. Smith, Qian Wu, Sindhu Cherian, Ajay K. Gopal	0
3	Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas 2025 ·Blood Advances ·Christina Poh, Jenna Voutsinas, Mazyar Shadman, Ryan C. Lynch, Edus H. Warren, (unknown), Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian Wu, Michi M. Shinohara, Ajay K. Gopal	1
4	Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis 2024 ·Transplantation and Cellular Therapy ·Christina Poh, Victor A. Chow, Ryan C. Lynch, Chaitra S. Ujjani, Edus H. Warren, Mazyar Shadman, Brian G. Till, (unknown), Jordan Gauthier, Alexandre V. Hirayama, Stephen D. Smith, Taranjit S. Gujral, Chihiro Morishima, (unknown), Jenna Voutsinas, (unknown), David G. Maloney, Ajay K. Gopal	0
5	Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up 2024 ·Blood ·Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, (unknown), Edus H. Warren, Mazyar Shadman, Brian G. Till, Chaitra S. Ujjani, Karolyn Morris, Heather Rasmussen, Jenna Voutsinas, Ajay K. Gopal	1
6	Development of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitors 2024 ·BMC Cancer ·(unknown), (unknown), Jenna Voutsinas, Brittany Barber, Zain H. Rizvi, Emily Marchiano, Rocco Ferrandino, Neal D. Futran, George E. Laramore, Jay J. Liao, Upendra Parvathaneni, Neil Panjwani, Renato Martins, Cristina P. Rodriguez, Qian Wu	1
7	Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Jenna Voutsinas, (unknown), Jonathan R. Fromm, Renato Martins, Keith D. Eaton, Rafael Santana-Dávila, Christina S. Baik, Sylvia Lee, Diane Tseng, Lei Deng, Brittany Barber, Emily Marchiano, George E. Laramore, Jay J. Liao, Simon S. Lo, Upendra Parvathaneni, Cristina P. Rodriguez	1
8	Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis 2023 ·Blood ·Christina Poh, Victor A. Chow, Ryan C. Lynch, Chaitra S. Ujjani, Mazyar Shadman, Brian G. Till, (unknown), Edus H. Warren, Jordan Gauthier, Stephen D. Smith, Taranjit S. Gujral, Chihiro Morishima, Qian Wu, Jenna Voutsinas, (unknown), (unknown), David G. Maloney, Ajay K. Gopal	1
9	Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel 2023 ·Blood ·(unknown), Jenna Voutsinas, Andrew J. Portuguese, Jennifer J. Huang, Emily C. Liang, Qian Wu, Xinyi Fan, Alexandre V. Hirayama, Erik L. Kimble, Lorenzo Iovino, Christina Poh, Ajay K. Gopal, Mazyar Shadman, Brian G. Till, Filippo Milano, Aude G. Chapuis, Ryan D. Cassaday, David G. Maloney, Jordan Gauthier	1
10	Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up 2023 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Ajay K. Gopal, Brian G. Till, Mazyar Shadman, Ryan C. Lynch, Andrew J. Cowan, Qian Wu, Jenna Voutsinas, (unknown), (unknown), Chaitra S. Ujjani, Ryan D. Cassaday, Jonathan R. Fromm, Min Fang, Stephen D. Smith	5
11	Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat 2022 ·Head & Neck ·(unknown), Qian Wu, Jenna Voutsinas, Jeffrey Houlton, Brittany Barber, Neal D. Futran, George E. Laramore, Jay J. Liao, Upendra Parvathaneni, Renato Martins, Jonathan R. Fromm, Cristina P. Rodriguez	11
12	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study 2021 ·The Lancet Haematology ·Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Jonathan R. Fromm, Andrew J. Cowan, Edus H. Warren, Mazyar Shadman, Andrei R. Shustov, Brian G. Till, Chaitra S. Ujjani, Edward N. Libby, Mary Philip, (unknown), (unknown), (unknown), Karolyn Morris, Heather Rasmussen, Fatemeh Behnia, Jenna Voutsinas, Ajay K. Gopal	33
13	Cancer survivorship care for young adults: a risk-stratified, multicenter randomized controlled trial to improve symptoms 2021 ·Journal of Cancer Survivorship ·Karen L. Syrjala, Casey Walsh, Jean C. Yi, Wendy M. Leisenring, (unknown), Jenna Voutsinas, Patricia A. Ganz, Linda A. Jacobs, Steven C. Palmer, Ann H. Partridge, K. Scott Baker	11
14	Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Leukemia Remission Confers a Leukemia-Free Survival Advantage 2021 ·Transplantation and Cellular Therapy ·Corinne Summers, Qian Wu, Colleen Annesley, Marie Bleakley, Ann Dahlberg, (unknown), Wenjun Huang, Jenna Voutsinas, Adam Brand, Wendy M. Leisenring, Michael C. Jensen, Julie R. Park, Rebecca Gardner	44
15	Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Solomon A. Graf, Ryan D. Cassaday, Karolyn Morris, Jenna Voutsinas, Qian Wu, Fatemeh Behnia, Ryan C. Lynch, Elizabeth F. Krakow, Heather Rasmussen, Thomas R. Chauncey, Sandra Kanan, Lorinda Soma, Stephen D. Smith, Ajay K. Gopal	10
16	Physical Activity, Hormone Therapy Use, and Stroke Risk among Women in the California Teachers Study Cohort 2020 ·Neuroepidemiology ·Charlie Zhong, Jenna Voutsinas, Joshua Z. Willey, Kamakshi Lakshminarayan, James V. Lacey, (unknown), Daniel Woo, Mitchell S.V. Elkind, Sophia Wang	3
17	Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors 2019 ·Clinical Cancer Research ·Ashwini Balakrishnan, Anusha Rajan, Alexander I. Salter, Paula L. Kosasih, Qian Wu, Jenna Voutsinas, Michael C. Jensen, Andreas Plückthun, Stanley R. Riddell	48
18	A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer 2019 ·Clinical Cancer Research ·Cristina P. Rodriguez, Qian Wu, Jenna Voutsinas, Jonathan R. Fromm, Xiuyun Jiang, Venu G. Pillarisetty, Sylvia M. Lee, Rafael Santana-Dávila, Bernardo Goulart, Christina S. Baik, Laura Q.M. Chow, Keith D. Eaton, Renato Martins	135
19	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy 2019 ·Blood ·Alexandre V. Hirayama, Jordan Gauthier, Kevin A. Hay, Jenna Voutsinas, Qian Wu, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Rachel N. Steinmetz, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle	121
20	The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis 2019 ·Haematologica ·Parimala Sonika Godavarthy, Rahul Kumar, Stefanie Herkt, Raquel Pereira, (unknown), (unknown), (unknown), Yosif Manavski, Tina Lucas, Kuan‐Ting Pan, Jenna Voutsinas, Qian Wu, Martin C. Müller, Susanne Saußele, Thomas Oellerich, Vivian G. Oehler, (unknown), Daniela S. Krause	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact